NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 7 April 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair Topics 1 & 2) Present for all items
2. Dr Lindsay Smith (Chair Topic 3) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Items 6 to 6.2.2
5. Professor Sofia Dias Items 5.1.3 to 6.2.2
6. Chris Herring Items 1 to 6.2
7. Dr Andrew Hitchings Present for all items
8. Dr Robert Hodgson Present for all items
9. Dr Bernard Khoo Present for all items
10. Dr Ivan Koychev Items 1 to 6.2
11. Dr Soo Fon Lim Present for all items
12. Professor David Meads Present for all items
13. Giles Monnickendam Present for all items
14. Dr Malcolm Oswald Present for all items
15. Professor Chris Parker Items 1 to 5.3.2
16. Dr Rebecca Payne Present for all items
17. Carole Pitkeathley Present for all items
18. Professor John Watkins Items 1 to 5.3.2

NICE staff present

Helen Knight, Programme Director Items 5 to 5.3.2

Linda Landells, Associate Director Present for all items

Kate Moore, Project Manager Items 1 to 4.2.2 & 6 to 6.2.2

Gavin Kenny, Project Manager Items 5 to 5.3.2

Charlie Hewitt, Heath Technology Assessment Adviser Items 1 to 4.2.2

Adam Brooke, Heath Technology Assessment Adviser Items 5 to 5.3.2

Caron Jones, Heath Technology Assessment Adviser Items 6 to 6.2.2

Raphael Egbu, Heath Technology Assessment Analyst Items 1 to 4.2.2

Thomas Jarratt, Heath Technology Assessment Analyst Items 1 to 4.2.2

Lewis Ralph, Heath Technology Assessment Analyst Items 1 to 4.2.2

Samuel Slayen, Heath Technology Assessment Analyst Items 1 to 4.2.2

Anna Willis, Heath Technology Assessment Analyst Items 1 to 4.2.2

Elizabeth Bell, Heath Technology Assessment Analyst Items 5 to 5.3.2

Anne Murray-Cota, Heath Technology Assessment Analyst Items 6 to 6.2.2

Emily Eaton Turner, Technical Analyst, Commercial Risk Assessment, Present for all items

Neha Jiandani, Technical Analyst, Commercial Liaison Items 1 to 5.3.2

Catrin Austin, Technical Analyst, Methods, and economics Items 6 to 6.2.2

Maroulla Whiteley, Business Analyst, RIA Present for all items

Olivia Havercroft, Senior Medical Editor Items 5 to 6.2.2

Laura Marsden, Public Involvement Adviser, PIP Items 5 to 5.3.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 6 to 6.2.2

Lucinda Evans, Coordinator, MIP Items 1 to 4.1.3 & 6 to 6.1.3

Lyn Davies Coordinator, MIP Items 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Mohammed Towhasir, Administrator, TA Items 1 to 4.2.2 & 6 to 6.2.2

Ismahan Abdullah, Administrator, TA Items 5 to 5.3.2

Hilary Eadon, Guidelines Commissioning Manager Items

External assessment group representatives present

Nigel Armstrong, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3 & 5 to 5.2.1

Willem Witlox, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3

Robert Wolff, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.2.1

Thea Van Asselt, Kleijnen Systematic Reviews Ltd (KSR) Items 6 to 6.1.3

Jeremy Howick, Kleijnen Systematic Reviews Ltd (KSR) Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Dr Patricia Fisher, Consultant Clinical Oncologist, Clinical expert nominated by AstraZeneca, items 1 to 4.1.3

Dr Elizabeth Toy, Consultant Clinical Oncologist, Clinical expert nominated by AstraZeneca, items 1 to 4.1.3

Steve Williamson, Deputy Cancer Drug Fund Clinical Lead, NHS England, items 1 to 4.2.2 & 6 to 6.2.2

Sinead Hayes, Patient expert nominated by SANE, items 5 to 5.2.1

Dr Mike Hunter, National Specialty Advisor for Adult Mental Health, Clinical expert nominated by NHS England and NHS Improvement, items 5 to 5.2.1

Professor Hamish McAllister-Williams, Professor of Affective Disorders, Clinical expert nominated by Janssen, items 5 to 5.2.1

Dr Sanjeev Patel, Innovative Medicines Fund Clinical lead, NHS England and NHS Improvement, items 5 to 5.2.1

Peter Pratt, National Specialist Mental Health Pharmacist advisor for Medicines in Mental Health, nominated by NHS England and NHS Improvement, items 5 to 5.2.1

## Minutes

### Introduction to the meeting

* 1. The chair Dr Megan John welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 10 March 2022.

### Appraisal of durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation - CDF review of TA578 [ID3885]

* 1. Part 1 – Open session
     1. The chair Dr Megan John welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Ivan Koychev declared professional and financial interests as he is in receipt of a NIHR fellowship in collaboration with AstraZeneca as part of which he is working with the cardiovascular and neuroscience teams to explore potential for repurposing of AstraZeneca portfolio agents for dementia. It was agreed his declaration would not prevent Dr Koychev from participating in discussions on this appraisal.
* Committee member Dr Matthew Bradley declared financial interests as he holds shares in AstraZeneca. As a direct conflict Dr Bradley did not participate in discussions on this appraisal.
* Nominated clinical expert Dr Patricia Fisher declared financial interests as in the last 12 months she has received speaker fees from AstraZeneca. It was agreed her declaration would not prevent Dr Fisher from providing expert advice to the committee.
* Nominated clinical expert Dr Elizabeth Toy declared financial interests as in the last 12 months she has received advisory board, honorarium, speaker fees and conference funding from Astra Zeneca and is a Co-Lead of GIRFT Lung Cancer Workstream. It was agreed her declarations would not prevent Dr Toy from providing expert advice to the committee.
* No further interests were declared for this item.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor David Meads, Dr Malcolm Oswald, and Professor Chris Parker
  1. Closed session (company representatives, clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10894>

### Appraisal of esketamine for treatment-resistant depression [ID1414]

* 1. Part 1 – Open session
     1. The chair Dr Megan John welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Janssen.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared an indirect financial interest as the University of Leeds has received funding from Janssen for research in an unrelated area. it was agreed his declaration would not prevent Professor Meads from participating in discussions on this appraisal
* Committee member Dr Ivan Koychev declared professional and financial interests as he has a collaboration with Janssen as part of which blood samples are analysed for biomarkers of neurodegeneration free of charge. The Oxford Department of Psychiatry has received funding from Janssen for an observational study in treatment resistant depression. He was not involved in the study. It was agreed his declaration would not prevent Dr Koychev from participating in discussions on this appraisal.
* Committee member Dr Matthew Bradley declared financial interests as he is an employee of GSK and hold shares in AstraZeneca, both companies are identified as potential competitors for esketamine. As a direct conflict Dr Bradley did not participate in discussion on this appraisal.
* Nominated clinical expert Professor Hamish McAllister-Williams declared financial and non-financial interests as he is currently recruiting participants to two commercial studies funded by COMPASS pathways and LivaNova. Over the last 3 years he has received fees for consultancy or talks at educational meetings from a number of pharmaceutical and neuromodulatory companies including: Lundbeck, Sunovian, LivaNova, Magstim, Syntropharma, Pfizer, P1vital, Janssen, Takeda and Go North Medical. It was agreed his declarations would not prevent Professor Hamish from providing expert advice to the committee.
* Nominated patient expert Sinead Hayes attended an advisory board on 16 August 2019 to give her experience of MDD and esketamine.

and a a training session on 5 November 2019. She made a video recording of her experience to be used internally at Janssen on 6 January 2020 and a Zoom interview on her experience for Janssen training purposes on 26 May 2020, on all these occasions her expenses were paid by Janssen. It was agreed her declarations would not prevent Sinead from providing expert advice to the committee.

* + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2a – Closed session (members of the public were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (company representatives, all experts and external assessment group representatives were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10371>

### Appraisal of pralsetinib for RET fusion-positive advanced non-small-cell lung cancer [ID3875]

* 1. Part 1 – Open session
     1. The chair Dr Lindsay Smith welcomed the NHSE expert, external assessment group representatives, members of the public and company representatives from Roche.
     2. The chair asked all committee members and the expert, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared indirect financial interest as the University of Leeds has received funding from BMS, Celgene and Sanofi for research in an unrelated area. it was agreed his declaration would not prevent Professor Meads from participating in discussions on this appraisal.
* Committee member Dr Ivan Koychev declared professional and financial interests as he has a collaboration with Roche developing a digital technology for the monitoring of cognitive function which has now concluded. It was agreed his declaration would not prevent Dr Koychev from participating in discussions on this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10770>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 5 May 2022 and will start promptly at 09.30.